Post by Genentech

#Breaking: The FDA approved our treatment for relapsing-remitting multiple sclerosis (RRMS) in pediatric patients 10 years of age and older who weigh 55 pounds or more. This approval represents an important milestone for children living with MS in the U.S. and their families, and can help close the longstanding gap in treatment options for children aged 10 and older. We look forward to continuing our commitment to the MS community and helping improve the lives of those living with this chronic condition. Learn more: http://spr.ly/6047BBml1R